One day in the not too distant future these two epigenetic pioneers will reach the state of critical mass and explode. It may be 6, 12, 18, 24 months away - we must be patient - it's coming and it's going to be big. Several catalysts are out there and any could start the reaction.

RVX-208 BetonMace Trial approved by FDA

RVX partners with BP

RVX acquired by BP

BetonMace trial successfully reaches endpoints

RVX Nasdaq listing

RVX upgraded to Strong Buy

RVX receives major institutional coverage

Resverlogix commences Phase 1 trial for promising new Alzheimers treatment

Resverlogix begins new trial on orphan indication

Zenith acquires Nasdaq listing

Zenith lists on TSX

ZEN-3694 success

Zenith announces new trial for treatment of breast cancer

RVX holds RVX-208 and about 2500 other compounds

ZEL holds ZEN-3694 and 1500 other compounds

To hold this 'diamond in the rough' at this point in time and at this price is an unbelievable opportunity - Hallelujah!

Chicagoest